Skip to main content

Articles

Page 4 of 108

  1. Breast cancer is a complex and heterogeneous disease with distinct subtypes and molecular profiles corresponding to different clinical outcomes. Mouse models of breast cancer are widely used, but their relevan...

    Authors: Carson D. Broeker, Mylena M. O. Ortiz, Michael S. Murillo and Eran R. Andrechek
    Citation: Breast Cancer Research 2023 25:120
  2. Triple negative breast cancer (TNBC) is a particularly aggressive and difficult-to-treat subtype of breast cancer that requires the development of novel therapeutic strategies. To pave the way for such develop...

    Authors: Katharina Jonas, Felix Prinz, Manuela Ferracin, Katarina Krajina, Barbara Pasculli, Alexander Deutsch, Tobias Madl, Beate Rinner, Ondrej Slaby, Christiane Klec and Martin Pichler
    Citation: Breast Cancer Research 2023 25:119
  3. Advanced glycation end products (AGEs) are reactive metabolites intrinsically linked with modern dietary patterns. Processed foods, and those high in sugar, protein and fat, often contain high levels of AGEs. ...

    Authors: Bradley A. Krisanits, Reid Schuster, Jaime Randise, Lourdes M. Nogueira, Jackson T. Lane, Gowtami A. Panguluri, Hong Li, Kristi Helke, Maria C. Cuitiño, Christopher Koivisto, Laura Spruill, Michael C. Ostrowski, Steven M. Anderson, David P. Turner and Victoria J. Findlay
    Citation: Breast Cancer Research 2023 25:118
  4. Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. The tumor immune microenv...

    Authors: Tessa G. Steenbruggen, Denise M. Wolf, Michael J. Campbell, Joyce Sanders, Sten Cornelissen, Bram Thijssen, Roberto A. Salgado, Christina Yau, Nick O-Grady, Amrita Basu, Rajith Bhaskaran, Lorenza Mittempergher, Gillian L. Hirst, Jean-Philippe Coppe, Marleen Kok, Gabe S. Sonke…
    Citation: Breast Cancer Research 2023 25:117
  5. The diagnostic accuracy of digital breast tomosynthesis (DBT) and digital mammography (DM) in breast cancer screening may vary per breast density subgroup. The purpose of this study was to evaluate which women...

    Authors: Jakob Olinder, Kristin Johnson, Anna Åkesson, Daniel Förnvik and Sophia Zackrisson
    Citation: Breast Cancer Research 2023 25:116
  6. B7 homology 4 (B7-H4), a potential target for cancer therapy, has been demonstrated to inhibit T cell cytotoxicity in the early stages of breast cancer. However, B7-H4 manipulating breast tumor immune microenv...

    Authors: Linlin Zhou, Jichun Wu, Mei Ruan, Yonglei Xiao, Hailin Lan, Qiongwen Wu, Chen-Wei Yu and Qiuyu Zhang
    Citation: Breast Cancer Research 2023 25:115
  7. About 20% of breast cancers in humans are basal-like, a subtype that is often triple-negative and difficult to treat. An effective translational model for basal-like breast cancer is currently lacking and urge...

    Authors: Joshua Watson, Tianfang Wang, Kun-Lin Ho, Yuan Feng, Tanakamol Mahawan, Kevin K. Dobbin and Shaying Zhao
    Citation: Breast Cancer Research 2023 25:114
  8. Women from socioeconomically deprived areas have lower breast cancer (BC) incidence rates for screen-detected oestrogen receptor (ER) + tumours and higher mortality for select tumour subtypes. We aimed to dete...

    Authors: Hayley M. Dunlop, Linda J. Williams, Peter S. Hall, Matthew Barber, Christine Dodds and Jonine D. Figueroa
    Citation: Breast Cancer Research 2023 25:106
  9. although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild ...

    Authors: Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Katherine Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Carolina Reduzzi, Paolo D’Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X. Ma…
    Citation: Breast Cancer Research 2023 25:112
  10. Latin American and Hispanic women are less likely to develop breast cancer (BC) than women of European descent. Observational studies have found an inverse relationship between the individual proportion of Nat...

    Authors: Linda Zollner, Diana Torres, Ignacio Briceno, Michael Gilbert, Gabriela Torres-Mejía, Joe Dennis, Manjeet K. Bolla, Qin Wang, Ute Hamann and Justo Lorenzo Bermejo
    Citation: Breast Cancer Research 2023 25:111
  11. Gene expression (GEX) signatures in breast cancer provide prognostic information, but little is known about their predictive value for tamoxifen treatment. We examined the tamoxifen-predictive value and progno...

    Authors: Christine Lundgren, Julia Tutzauer, Sarah E. Church, Olle Stål, Maria Ekholm, Carina Forsare, Bo Nordenskjöld, Mårten Fernö, Pär-Ola Bendahl and Lisa Rydén
    Citation: Breast Cancer Research 2023 25:110
  12. Triple-negative breast cancer (TNBC) is a subtype of breast cancer with higher aggressiveness and poorer outcomes. Recently, long non-coding RNAs (lncRNAs) have become the crucial gene regulators in the progre...

    Authors: Dan Luo, Yiran Liang, Yajie Wang, Fangzhou Ye, Yuhan Jin, Yaming Li, Dianwen Han, Zekun Wang, Bing Chen, Wenjing Zhao, Lijuan Wang, Xi Chen, Liyu Jiang and Qifeng Yang
    Citation: Breast Cancer Research 2023 25:109
  13. Breast cancer liver metastases (BCLM) is a common cause of breast cancer-related death. The prognostic and predictive value of receptor expression and St Gallen classification is challenged by receptor status ...

    Authors: Marcus Sundén, Sofia Norgren, Robert Lundqvist, Anne Andersson, Malin Sund and Oskar Hemmingsson
    Citation: Breast Cancer Research 2023 25:105
  14. Obesity is an established risk factor for breast cancer in postmenopausal women. However, the underlying biological mechanisms of how obesity contributes to breast cancer remains unclear. The inflammatory adip...

    Authors: Rhianna Rachael Romany Blyth, Charles N. Birts and Stephen A. Beers
    Citation: Breast Cancer Research 2023 25:104
  15. The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor–po...

    Authors: P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty…
    Citation: Breast Cancer Research 2023 25:103
  16. Intratumor heterogeneity is a well-established hallmark of cancer that impedes cancer research, diagnosis, and treatment. Previously, we phenotypically sorted human breast cancer cells based on migratory poten...

    Authors: Lauren A. Hapach, Wenjun Wang, Samantha C. Schwager, Devika Pokhriyal, Emily D. Fabiano and Cynthia A. Reinhart-King
    Citation: Breast Cancer Research 2023 25:102
  17. The interface zone, area around invasive carcinoma, can be thought of as the actual tissue of the tumor microenvironment with precedent alterations for tumor invasion. However, the heterogeneity and characteri...

    Authors: Wei Yang, Meiyu Xu, Shuoqi Xu, Qingxian Guan, Shuaiming Geng, Juanhong Wang, Wei Wei, Hongwei Xu, Ying Liu, Yong Meng and Ming-Qing Gao
    Citation: Breast Cancer Research 2023 25:100
  18. Obesity increases breast cancer risk and breast cancer-specific mortality, particularly for people with estrogen receptor (ER)-positive tumors. Body mass index (BMI) is used to define obesity, but it may not b...

    Authors: Marisol Castillo-Castrejon, Barbara Mensah Sankofi, Stevi Johnson Murguia, Abasi-ama Udeme, Hoaning Howard Cen, Yi Han Xia, Nisha S. Thomas, William L. Berry, Kenneth L. Jones, Vincent R. Richard, Rene P. Zahedi, Christoph H. Borchers, James D. Johnson and Elizabeth A. Wellberg
    Citation: Breast Cancer Research 2023 25:99
  19. Emerging data indicate that variations in quantitative epithelial and stromal tissue composition and their relative abundance in benign breast biopsies independently impact risk of future invasive breast cance...

    Authors: Mustapha Abubakar, Alyssa Klein, Shaoqi Fan, Scott Lawrence, Karun Mutreja, Jill E. Henry, Ruth M. Pfeiffer, Maire A. Duggan and Gretchen L. Gierach
    Citation: Breast Cancer Research 2023 25:97
  20. Targeted estrogen receptor degradation has been approved to effectively treat ER + breast cancers. Due to the poor bioavailability of fulvestrant, the first generation of SERD, many efforts were made to develo...

    Authors: Feng Zhou, Guimei Yang, Liting Xue, Yajing Liu, Yao Guo, Ji Zhu, Linlin Yuan, Peng Gu, Feng Tang, Jinwen Shan and Renhong Tang
    Citation: Breast Cancer Research 2023 25:96
  21. Laboratory studies have indicated that a cholesterol metabolite and selective estrogen receptor modulator, 27-hydroxycholesterol (27HC), may be important in breast cancer etiology and explain associations betw...

    Authors: Mindy C. DeRouen, Juan Yang, Yuqing Li, Adrian A. Franke, Anne N. Tome, Kami K. White, Brenda Y. Hernandez, Yurii Shvetsov, Veronica Setiawan, Anna H. Wu, Lynne R. Wilkens, Loïc Le Marchand, Lenora W. M. Loo and Iona Cheng
    Citation: Breast Cancer Research 2023 25:95
  22. Authors: M. G. Muoio, M. Pellegrino, V. Rapicavoli, M. Talia, G. Scavo, V. Sergi, V. Vella, S. Pettinato, M. G. Galasso, R. Lappano, D. Scordamaglia, F. Cirillo, A. Pulvirenti, D. C. Rigiracciolo, M. Maggiolini, A. Belfiore…
    Citation: Breast Cancer Research 2023 25:94

    The original article was published in Breast Cancer Research 2023 25:84

  23. Genome-wide studies of gene–environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~...

    Authors: Pooja Middha, Xiaoliang Wang, Sabine Behrens, Manjeet K. Bolla, Qin Wang, Joe Dennis, Kyriaki Michailidou, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Thaïs Baert, Laura E. Beane Freeman…
    Citation: Breast Cancer Research 2023 25:93
  24. Breast density is strongly associated with breast cancer risk. Fully automated quantitative density assessment methods have recently been developed that could facilitate large-scale studies, although data on a...

    Authors: Laurel A. Habel, Stacey E. Alexeeff, Ninah Achacoso, Vignesh A. Arasu, Aimilia Gastounioti, Lawrence Gerstley, Robert J. Klein, Rhea Y. Liang, Jafi A. Lipson, Walter Mankowski, Laurie R. Margolies, Joseph H. Rothstein, Daniel L. Rubin, Li Shen, Adriana Sistig, Xiaoyu Song…
    Citation: Breast Cancer Research 2023 25:92
  25. A hallmark of many malignant tumors is dedifferentiated (immature) cells bearing slight or no resemblance to the normal cells from which the cancer originated. Tumor dedifferentiated cells exhibit a higher cap...

    Authors: Nuria G. Martínez-Illescas, Silvia Leal, Patricia González, Osvaldo Graña-Castro, Juan José Muñoz-Oliveira, Alfonso Cortés-Peña, María Gómez-Gil, Zaira Vega, Verónica Neva, Andrea Romero, Miguel Quintela-Fandino, Eva Ciruelos, Consuelo Sanz, Sofía Aragón, Leisy Sotolongo, Sara Jiménez…
    Citation: Breast Cancer Research 2023 25:91
  26. The communication between tumor cells and tumor microenvironment plays a critical role in cancer development. Cancer-associated fibroblasts (CAFs) are the major components of the tumor microenvironment and tak...

    Authors: Huijuan Dai, Wenting Xu, Lulu Wang, Xiao Li, Xiaonan Sheng, Lei Zhu, Ye Li, Xinrui Dong, Weihang Zhou, Chenyu Han, Yan Mao and Linli Yao
    Citation: Breast Cancer Research 2023 25:90
  27. Cardiovascular disease (CVD) is the leading cause of death worldwide. The aim of this study was to examine if CVD affects the mortality of women after a breast cancer diagnosis and population controls differen...

    Authors: Annika Möhl, Sabine Behrens, Fabian Flaßkamp, Nadia Obi, Annika Kreienbrinck, Bernd Holleczek, Kathleen Gali, Jenny Chang-Claude and Heiko Becher
    Citation: Breast Cancer Research 2023 25:89
  28. Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer, with limited therapeutic options readily available. Immunotherapy such as immune checkpoint inhibition has been investigated in...

    Authors: Chanjuan Zheng, Xi Xu, Muyao Wu, Lian Xue, Jianyu Zhu, Hongzhuo Xia, Siyu Ding, Shujun Fu, Xinyu Wang, Yian Wang, Guangchun He, Xia Liu and Xiyun Deng
    Citation: Breast Cancer Research 2023 25:88
  29. Deep learning analysis of radiological images has the potential to improve diagnostic accuracy of breast cancer, ultimately leading to better patient outcomes. This paper systematically reviewed the current li...

    Authors: Richard Adam, Kevin Dell’Aquila, Laura Hodges, Takouhie Maldjian and Tim Q. Duong
    Citation: Breast Cancer Research 2023 25:87
  30. Carcinoma-associated fibroblasts (CAFs) play a critical role in cancer progression and immune cell modulation. In this study, it was aimed to evaluate the roles of CAFs-derived IL-6 in doxorubicin (Dox) resist...

    Authors: Nisa Chuangchot, Pranisa Jamjuntra, Supaporn Yangngam, Piriya Luangwattananun, Suyanee Thongchot, Mutita Junking, Peti Thuwajit, Pa-Thai Yenchitsomanus and Chanitra Thuwajit
    Citation: Breast Cancer Research 2023 25:86
  31. Chemoresistance involves metastasis and aggressiveness of breast cancer (BC). Chemotherapy-elicited exosomes have been reported to be associated with drug resistance and pro-metastatic capacity of BC cells. No...

    Authors: Wenjie Xia, Wuzhen Chen, Chao Ni, Xuli Meng, Jun Wu, Qiong Yang, Hongchao Tang, Hongjun Yuan and Shan Fang
    Citation: Breast Cancer Research 2023 25:85
  32. The receptor for advanced glycation end products (RAGE) is implicated in diabetes and obesity complications, as well as in breast cancer (BC). Herein, we evaluated whether RAGE contributes to the oncogenic act...

    Authors: M. G. Muoio, M. Pellegrino, V. Rapicavoli, M. Talia, G. Scavo, V. Sergi, V. Vella, S. Pettinato, M. G. Galasso, R. Lappano, D. Scordamaglia, F. Cirillo, A. Pulvirenti, D. C. Rigiracciolo, M. Maggiolini, A. Belfiore…
    Citation: Breast Cancer Research 2023 25:84

    The Publisher Correction to this article has been published in Breast Cancer Research 2023 25:94

  33. Microbial dysbiosis has emerged as an important element in the development and progression of various cancers, including breast cancer. However, the microbial composition of the breast from healthy individuals...

    Authors: Rana German, Natascia Marino, Chris Hemmerich, Ram Podicheti, Douglas B. Rusch, Leah T. Stiemsma, Hongyu Gao, Xiaoling Xuei, Pam Rockey and Anna Maria Storniolo
    Citation: Breast Cancer Research 2023 25:82
  34. Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood–brain barrier (BBB) pene...

    Authors: Jian Zhang, Nicholas P. McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo, Mei Wang, Kan Chen, Wenlei Yu and Xichun Hu
    Citation: Breast Cancer Research 2023 25:81
  35. Some breast carcinomas detected at screening, especially ductal carcinoma in situ, may have limited potential for progression to symptomatic disease. To determine non-progression is a challenge, but if all scr...

    Authors: Torunn Heggland, Lars Johan Vatten, Signe Opdahl and Harald Weedon-Fekjær
    Citation: Breast Cancer Research 2023 25:80
  36. There are few prospective studies on the correlations between MRI features and whole RNA-sequencing data in breast cancer according to molecular subtypes. The purpose of our study was to explore the associatio...

    Authors: Ah Young Park, Mi-Ryung Han, Bo Kyoung Seo, Hye-Yeon Ju, Gil Soo Son, Hye Yoon Lee, Young Woo Chang, Jungyoon Choi, Kyu Ran Cho, Sung Eun Song, Ok Hee Woo and Hyun Soo Park
    Citation: Breast Cancer Research 2023 25:79
  37. New drugs for locally advanced or metastatic breast cancer have led to clinical benefits, aside with increasing costs to healthcare systems. The current financing model for health technology assessment (HTA) p...

    Authors: Filipa Alves da Costa, Fábio Cardoso Borges, Adriana Ramos, Alexandra Mayer, Claudia Brito, Catarina Ramos, Catarina Bernardo, Mariane Cossito, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana da Costa Miranda and António Lourenço
    Citation: Breast Cancer Research 2023 25:78
  38. The immunohistochemical test (IHC) of HER2 and HR can provide prognostic information and treatment guidance for invasive breast cancer patients. We aimed to develop noninvasive image signatures ISHER2 and ISHR of...

    Authors: Xinzhi Teng, Jiang Zhang, Xinyu Zhang, Xinyu Fan, Ta Zhou, Yu-hua Huang, Lu Wang, Elaine Yuen Phin Lee, Ruijie Yang and Jing Cai
    Citation: Breast Cancer Research 2023 25:77
  39. FOXM1 (Forkhead box M1) is an oncogenic transcription factor that is greatly upregulated in breast cancer and many other cancers where it promotes tumorigenesis, and cancer growth and progression. It is expres...

    Authors: Benita S. Katzenellenbogen, Valeria Sanabria Guillen and John A. Katzenellenbogen
    Citation: Breast Cancer Research 2023 25:76
  40. DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNA...

    Authors: Yue Zhang, Lianqiu Lv, Renjing Zheng, Rong Xie, Yuanhang Yu, Han Liao, Jianying Chen and Bo Zhang
    Citation: Breast Cancer Research 2023 25:75
  41. RHAMM is a multifunctional protein that is upregulated in breast tumors, and the presence of strongly RHAMM+ve cancer cell subsets associates with elevated risk of peripheral metastasis. Experimentally, RHAMM imp...

    Authors: Cornelia Tolg, Maja Milojevic, Freda W. Qi, Hailie A. Pavanel, M. Elizabeth O. Locke, Jenny Ma, Mathew Price, Andrew C. Nelson, James B. McCarthy, Kathleen A. Hill and Eva A. Turley
    Citation: Breast Cancer Research 2023 25:74
  42. Height, body mass index (BMI), and weight gain are associated with breast cancer risk in the general population. It is unclear whether these associations also exist for carriers of pathogenic variants in the BRCA...

    Authors: Karin Kast, Esther M. John, John L. Hopper, Nadine Andrieu, Catherine Noguès, Emmanuelle Mouret-Fourme, Christine Lasset, Jean-Pierre Fricker, Pascaline Berthet, Véronique Mari, Lucie Salle, Marjanka K. Schmidt, Margreet G. E. M. Ausems, Encarnacion B. Gomez Garcia, Irma van de Beek, Marijke R. Wevers…
    Citation: Breast Cancer Research 2023 25:72
  43. The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which pati...

    Authors: M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips and G. S. Sonke
    Citation: Breast Cancer Research 2023 25:71

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.1
    5-year Journal Impact Factor: 7.1
    Source Normalized Impact per Paper (SNIP): 1.865
    SCImago Journal Rank (SJR): 2.578

    Speed 2023
    Submission to first editorial decision (median days): 14
    Submission to acceptance (median days): 129

    Usage 2023
    Downloads: 2,432,781
    Altmetric mentions: 1,561